Registration Information for Herantis Pharma’s Webinar on the Cerebral Dopamine Neurotrophic Factor (CDNF) Phase I-II Data Readout
Herantis Pharma Plc (“Herantis” or “Company”) today announces the registration information for the upcoming webinar that will highlight more details on CDNF Phase I-II Study Met Primary Endpoints of Safety and Tolerability at 12 months (link to press release) . Event Details: CDNF Phase I-II Study Met Primary Endpoints of Safety and Tolerability at 12 months Date and Time: September 15, 2020 at 15:00 – 16:00 CETPresenters: Craig